Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, open-label, multicenter clinical trial of pegylated liposomal doxorubicin (Caelyx) [doxorubicin liposomal] as primary treatment for patients with breast cancer and a history of heart disease or age over 65 years

Trial Profile

A phase II, open-label, multicenter clinical trial of pegylated liposomal doxorubicin (Caelyx) [doxorubicin liposomal] as primary treatment for patients with breast cancer and a history of heart disease or age over 65 years

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms CAPRICE
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Dec 2017 Results of the final analysis, presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 12 Nov 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top